Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance
Executive Summary
Phase II data presented at CROI aren't sufficient to demonstrate statistical superiority over ViiV's Tivicay, but one analyst predicts that a repeat performance in larger Phase III trials could support a superiority claim.
You may also be interested in...
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead hopes Biktarvy will enable it to win market share away from ViiV's dolutegravir-containing regimens, but ViiV filed a patent infringement case within hours of the US FDA approval of Gilead's new combo.
Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen
The latest HIV drug development news and highlights from our FDA Performance Tracker.
Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?